NeuroMetrix to Exhibit at The Endocrine Society Annual Meeting "ENDO 2011"

WALTHAM, Mass., Jun 01, 2011 (BUSINESS WIRE) --

NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it will exhibit at the annual meeting of The Endocrine Society in Boston on June 4-6, 2011. The exhibition will include a demonstration of its newest product - NC-stat^®|DPNCheck^™ which is a fast, accurate, and quantitative test for the evaluation of systemic neuropathies such as diabetic peripheral neuropathy (DPN).

NC-stat DPNCheck Benefits

• May aid in the early detection, confirmation, and monitoring of DPN
• Measures sural nerve conduction velocity - a standard biomarker for subclinical and symptomatic DPN
• Sensitive and specific for DPN^1,2, and predictive of its complications³
• Straightforward clinical interpretation
• Cost effective

"We are excited to preview NC-stat DPNCheck at ENDO 2011 as it a key milestone in our aggressive timetable to launch this product into the diabetes market," said Shai N. Gozani M.D., PhD., President and Chief Executive Officer of NeuroMetrix. "This point-of-care device should help address the need for a widely available, objective and standardized test for diabetic neuropathy."

NeuroMetrix encourages ENDO 2011 attendees to stop by booth #833-835 to:

• Learn more about NC-stat DPNCheck.
• View a live demonstration.
• Inquire about a no-obligation evaluation.
• Meet with NeuroMetrix representatives.

The device is a modified version of the widely used NC-stat^® device which has been shown to accurately detect DPN^1,2. NC-stat DPNCheck will be commercially available in the second half of the year. To learn more, click here.

About NeuroMetrix

NeuroMetrix is a science-based health care company transforming patient care through neurotechnology. We develop and market innovative products for the detection, diagnosis, and monitoring of peripheral nerve and spinal cord disorders such as those associated with diabetes, carpal tunnel syndrome, lumbosacral disc disease and spinal stenosis. For more information, visit http://www.neurometrix.com.

References

¹Perkins BA, Orszag A, Grewal J, NG E, Ngo M, Bril V. Validation of a Novel Point-of-Care Nerve Conduction Device for the Detection of Diabetic Sensorimotor Polyneuropathy. Diabetes Care. September 2006;29(9): 2023-2027.

²Perkins BA, Orszag A, Grewal J, NG E, Ngo M, Bril V. Multi-Site Testing with a Point-of-Care Nerve Conduction Device Can Be Used in an Algorithm to Diagnose Diabetic Sensorimotor Polyneuropathy. Diabetes Care. March 2008;31(3): 522-524.

³Pambianco G, et al. The Assessment of Clinical Distal Symmetric Polyneuropathy in Type 1 Diabetes: A Comparison of Methodologies from the Pittsburgh Epidemiology of Diabetes Complications Cohort. Diabetes Research & Clinical Practice (2011), doi:10.1016/j.diabres.2011.02.005.

SOURCE: NeuroMetrix

NeuroMetrix, Inc.
Thomas T. Higgins, 781-314-2761
CFO
neurometrix.ir@neurometrix.com